RiverPark Advisors LLC Purchases New Position in CareDx, Inc. $CDNA

RiverPark Advisors LLC purchased a new position in shares of CareDx, Inc. (NASDAQ:CDNA) during the second quarter, Holdings Channel reports. The firm purchased 7,624 shares of the company’s stock, valued at approximately $149,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Sei Investments Co. grew its stake in CareDx by 1.7% in the 1st quarter. Sei Investments Co. now owns 47,921 shares of the company’s stock valued at $851,000 after acquiring an additional 816 shares during the period. Fuller & Thaler Asset Management Inc. increased its stake in shares of CareDx by 3.9% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 23,925 shares of the company’s stock worth $425,000 after purchasing an additional 900 shares in the last quarter. MCF Advisors LLC raised its position in shares of CareDx by 292.9% during the 2nd quarter. MCF Advisors LLC now owns 1,336 shares of the company’s stock worth $26,000 after purchasing an additional 996 shares during the last quarter. Cetera Trust Company N.A lifted its stake in CareDx by 11.2% in the 2nd quarter. Cetera Trust Company N.A now owns 12,195 shares of the company’s stock valued at $238,000 after buying an additional 1,225 shares in the last quarter. Finally, US Bancorp DE boosted its holdings in CareDx by 7.2% in the 1st quarter. US Bancorp DE now owns 18,403 shares of the company’s stock worth $327,000 after buying an additional 1,235 shares during the last quarter.

CareDx Trading Down 0.3%

CareDx stock opened at $17.90 on Wednesday. CareDx, Inc. has a 12-month low of $10.96 and a 12-month high of $26.37. The stock has a market cap of $920.65 million, a P/E ratio of 17.55 and a beta of 2.50. The company has a 50-day moving average price of $15.23 and a 200 day moving average price of $15.58.

CareDx (NASDAQ:CDNA) last posted its earnings results on Tuesday, November 4th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.15. The company had revenue of $100.06 million during the quarter, compared to analysts’ expectations of $95.25 million. CareDx had a return on equity of 18.03% and a net margin of 17.97%.The firm’s quarterly revenue was up 20.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.14) earnings per share. CareDx has set its FY 2025 guidance at EPS. As a group, analysts forecast that CareDx, Inc. will post -0.9 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on CDNA. Weiss Ratings reissued a “hold (c-)” rating on shares of CareDx in a report on Wednesday, November 19th. Zacks Research raised CareDx from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 18th. William Blair initiated coverage on shares of CareDx in a research note on Tuesday, August 26th. They set a “market perform” rating on the stock. BTIG Research increased their target price on shares of CareDx from $22.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Finally, Wall Street Zen raised shares of CareDx from a “sell” rating to a “buy” rating in a research note on Saturday, November 8th. Four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, CareDx currently has an average rating of “Hold” and an average target price of $26.00.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.